Atossa Therapeutics Receives FDA “Study May Proceed” Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
SEATTLE, Jan. 6, 2026 /PRNewswire/ — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet…
